Paclitaxel - DOR BioPharma
Alternative Names: LPE/PLP paclitaxel; Paclitaxel LPE/PLPLatest Information Update: 15 Jan 2022
At a glance
- Originator DOR BioPharma
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jun 2003 Preclinical trials in Cancer in USA (PO)